[go: up one dir, main page]

PT3182975T - Comprimidos com concentração de alta dosagem de rucaparib - Google Patents

Comprimidos com concentração de alta dosagem de rucaparib

Info

Publication number
PT3182975T
PT3182975T PT158330969T PT15833096T PT3182975T PT 3182975 T PT3182975 T PT 3182975T PT 158330969 T PT158330969 T PT 158330969T PT 15833096 T PT15833096 T PT 15833096T PT 3182975 T PT3182975 T PT 3182975T
Authority
PT
Portugal
Prior art keywords
rucaparib
high dosage
dosage strength
strength tablets
tablets
Prior art date
Application number
PT158330969T
Other languages
English (en)
Original Assignee
Pharma& Schweiz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma& Schweiz Gmbh filed Critical Pharma& Schweiz Gmbh
Publication of PT3182975T publication Critical patent/PT3182975T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT158330969T 2014-08-22 2015-08-17 Comprimidos com concentração de alta dosagem de rucaparib PT3182975T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
PT3182975T true PT3182975T (pt) 2025-10-28

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158330969T PT3182975T (pt) 2014-08-22 2015-08-17 Comprimidos com concentração de alta dosagem de rucaparib

Country Status (20)

Country Link
US (3) US9987285B2 (pt)
EP (1) EP3182975B1 (pt)
JP (3) JP6574477B2 (pt)
KR (2) KR20170043597A (pt)
CN (2) CN113209033A (pt)
AU (2) AU2015305696B2 (pt)
BR (1) BR112017000865A2 (pt)
CA (1) CA2955495C (pt)
DK (1) DK3182975T3 (pt)
ES (1) ES3048688T3 (pt)
FI (1) FI3182975T3 (pt)
IL (1) IL249946B (pt)
LT (1) LT3182975T (pt)
MX (1) MX367260B (pt)
NZ (1) NZ728392A (pt)
PT (1) PT3182975T (pt)
RS (1) RS67356B1 (pt)
RU (1) RU2705156C2 (pt)
SG (1) SG11201700265VA (pt)
WO (1) WO2016028689A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RU2705156C2 (ru) 2014-08-22 2019-11-05 Кловис Онколоджи, Инк. Таблетки, содержащие большую дозу рукапариба
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
EP3687505A1 (en) * 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
MA51524A (fr) 2018-01-05 2020-11-11 Cybrexa 1 Inc Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
CN114302744B (zh) 2019-07-10 2025-08-26 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
DK4143182T3 (da) 2020-04-28 2025-03-03 Rhizen Pharmaceuticals Ag Nye forbindelser, der er anvendelige som poly(adp-ribose)-polymerase (parp)-hæmmere
WO2022015557A1 (en) 2020-07-14 2022-01-20 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023011793A (es) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
CN118215467A (zh) * 2021-11-10 2024-06-18 克里蒂泰克公司 鲁卡帕尼颗粒及其用途
US20250223295A1 (en) 2022-01-11 2025-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50031B (sr) 1999-01-11 2008-11-28 Agouron Pharmaceuticals Inc., Triciklični inhibitori poli(adp-riboza)polimeraza
WO2004087713A1 (en) 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
PL1660095T3 (pl) 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
RU2361592C2 (ru) 2004-09-22 2009-07-20 Пфайзер Инк. Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
KR100853601B1 (ko) 2004-09-22 2008-08-22 화이자 인코포레이티드 8-플루오로-2-{4-[(메틸아미노)메틸]페닐}-1,3,4,5-테트라하이드로-6H-아제피노[5,4,3-cd]인돌-6-온의포스페이트 염의 다형성 및 무정형 형태
KR100876520B1 (ko) 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(adp-리보오스) 폴리머라제 억제제의 제조 방법
JP2011516527A (ja) * 2008-04-09 2011-05-26 レツク・フアーマシユーテイカルズ・デー・デー 医薬品有効成分の造粒
JP5745283B2 (ja) * 2010-02-12 2015-07-08 ファイザー・インク 8−フルオロ−2−{4−[(メチルアミノ)メチル]フェニル}−1,3,4,5−テトラヒドロ−6H−アゼピノ[5,4,3−cd]インドール−6−オンの塩および多形体
JP2015515478A (ja) * 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法
RU2705156C2 (ru) 2014-08-22 2019-11-05 Кловис Онколоджи, Инк. Таблетки, содержащие большую дозу рукапариба

Also Published As

Publication number Publication date
KR20230097211A (ko) 2023-06-30
IL249946B (en) 2020-05-31
LT3182975T (lt) 2025-11-25
JP7127101B2 (ja) 2022-08-29
AU2015305696B2 (en) 2019-08-29
ES3048688T3 (en) 2025-12-11
IL249946A0 (en) 2017-03-30
EP3182975A4 (en) 2018-04-18
JP6574477B2 (ja) 2019-09-11
SG11201700265VA (en) 2017-02-27
JP2017525712A (ja) 2017-09-07
MX367260B (es) 2019-08-12
NZ728392A (en) 2023-06-30
RS67356B1 (sr) 2025-11-28
DK3182975T3 (da) 2025-10-20
RU2705156C2 (ru) 2019-11-05
EP3182975B1 (en) 2025-10-01
JP2020002149A (ja) 2020-01-09
US20180200260A1 (en) 2018-07-19
RU2017109139A (ru) 2018-09-24
AU2015305696A1 (en) 2017-02-02
KR20170043597A (ko) 2017-04-21
CA2955495C (en) 2023-09-19
US20190099430A1 (en) 2019-04-04
KR102803917B1 (ko) 2025-05-07
MX2017001540A (es) 2017-05-11
FI3182975T3 (fi) 2025-11-13
US20160051561A1 (en) 2016-02-25
BR112017000865A2 (pt) 2017-12-05
US9987285B2 (en) 2018-06-05
CN113209033A (zh) 2021-08-06
AU2019272064A1 (en) 2019-12-19
JP2021038242A (ja) 2021-03-11
CN106794185A (zh) 2017-05-31
RU2017109139A3 (pt) 2019-03-06
AU2019272064B2 (en) 2021-11-18
US10130636B2 (en) 2018-11-20
WO2016028689A1 (en) 2016-02-25
EP3182975A1 (en) 2017-06-28
JP6797980B2 (ja) 2020-12-09
CA2955495A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
ES3048688T3 (en) High dosage strength tablets of rucaparib
IL270954A (en) Pharmaceutical compounds
SG11201702298VA (en) Pharmaceutical preparation
GB201416513D0 (en) Pharmaceutical compounds
GB201417707D0 (en) Pharmaceutical compounds
IL246613A0 (en) Dosing regimen of iron trimaltol
IL249374A0 (en) Pharmaceutical administration forms
IL249130B (en) Preparation of piperidine-4-carbothioamide
GB201415811D0 (en) Solid dosage form production
AU358389S (en) Pharmaceutical capsule
GB201508022D0 (en) Pharmaceutical compounds
PH32014000079S1 (en) Pharmaceutical tablet
GB201502041D0 (en) Solid dosage form production
GB201416968D0 (en) Pharmaceutical compounds
GB201416969D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds
GB201402278D0 (en) Pharmaceutical compounds
GB201402013D0 (en) Pharmaceutical compounds
GB201401478D0 (en) Pharmaceutical compounds